A mighty oak in the rapidly expanding field of checkpoint inhibition for NSCLC
In the Lancet issue of last December Rittmeyer and colleagues reported the primary efficacy analysis of another landmark immunotherapy study (1): the randomized phase 3 OAK trial comparing atezolizumab (n=425), an anti-programmed death-ligand 1 (PD-L1) monoclonal antibody, with docetaxel (n=425) for...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) Editorial |
| Sprache: | Englisch |
| Veröffentlicht: |
Feb 09, 2017
|
| In: |
Journal of thoracic disease
Year: 2017, Jahrgang: 9, Heft: 3, Pages: E292-E294 |
| ISSN: | 2077-6624 |
| DOI: | 10.21037/jtd.2017.02.86 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.21037/jtd.2017.02.86 Verlag, kostenfrei, Volltext: http://jtd.amegroups.com/article/view/12412 
|
| Verfasserangaben: | Petros Christopoulos, Michael Thomas |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1577797191 | ||
| 003 | DE-627 | ||
| 005 | 20230426230719.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180720s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21037/jtd.2017.02.86 |2 doi | |
| 035 | |a (DE-627)1577797191 | ||
| 035 | |a (DE-576)507797191 | ||
| 035 | |a (DE-599)BSZ507797191 | ||
| 035 | |a (OCoLC)1341013907 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Christopoulos, Petros |d 1977- |e VerfasserIn |0 (DE-588)138659702 |0 (DE-627)604886756 |0 (DE-576)308488067 |4 aut | |
| 245 | 1 | 2 | |a A mighty oak in the rapidly expanding field of checkpoint inhibition for NSCLC |c Petros Christopoulos, Michael Thomas |
| 264 | 1 | |c Feb 09, 2017 | |
| 300 | |a 3 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 20.07.2018 | ||
| 520 | |a In the Lancet issue of last December Rittmeyer and colleagues reported the primary efficacy analysis of another landmark immunotherapy study (1): the randomized phase 3 OAK trial comparing atezolizumab (n=425), an anti-programmed death-ligand 1 (PD-L1) monoclonal antibody, with docetaxel (n=425) for patients with squamous or adenocarcinomatous non-small cell lung cancer (NSCLC) progressing after one or more platinum-based combination regimens. | ||
| 700 | 1 | |a Thomas, Michael |e VerfasserIn |0 (DE-588)1054438781 |0 (DE-627)79152213X |0 (DE-576)41027089X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of thoracic disease |d Hong Kong : AME Publishing Company, 2009 |g 9(2017), 3, Seite E292-E294 |h Online-Ressource |w (DE-627)635603896 |w (DE-600)2573571-8 |w (DE-576)330413570 |x 2077-6624 |7 nnas |a A mighty oak in the rapidly expanding field of checkpoint inhibition for NSCLC |
| 773 | 1 | 8 | |g volume:9 |g year:2017 |g number:3 |g pages:E292-E294 |g extent:3 |a A mighty oak in the rapidly expanding field of checkpoint inhibition for NSCLC |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21037/jtd.2017.02.86 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://jtd.amegroups.com/article/view/12412 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180720 | ||
| 993 | |a Editorial | ||
| 994 | |a 2017 | ||
| 998 | |g 1054438781 |a Thomas, Michael |m 1054438781:Thomas, Michael |d 910000 |d 950000 |d 950900 |e 910000PT1054438781 |e 950000PT1054438781 |e 950900PT1054438781 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 2 |y j | ||
| 998 | |g 138659702 |a Christopoulos, Petros |m 138659702:Christopoulos, Petros |d 910000 |d 950000 |d 950900 |e 910000PC138659702 |e 950000PC138659702 |e 950900PC138659702 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 1 |x j | ||
| 999 | |a KXP-PPN1577797191 |e 3019022924 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"name":{"displayForm":["Petros Christopoulos, Michael Thomas"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"extent":"3 S."}],"id":{"eki":["1577797191"],"doi":["10.21037/jtd.2017.02.86"]},"title":[{"title_sort":"mighty oak in the rapidly expanding field of checkpoint inhibition for NSCLC","title":"A mighty oak in the rapidly expanding field of checkpoint inhibition for NSCLC"}],"person":[{"role":"aut","given":"Petros","display":"Christopoulos, Petros","family":"Christopoulos"},{"family":"Thomas","display":"Thomas, Michael","given":"Michael","role":"aut"}],"note":["Gesehen am 20.07.2018"],"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"Feb 09, 2017"}],"relHost":[{"titleAlt":[{"title":"JTD"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"A mighty oak in the rapidly expanding field of checkpoint inhibition for NSCLCJournal of thoracic disease","physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Journal of thoracic disease","title":"Journal of thoracic disease"}],"part":{"year":"2017","pages":"E292-E294","text":"9(2017), 3, Seite E292-E294","volume":"9","extent":"3","issue":"3"},"pubHistory":["1.2009 -"],"origin":[{"dateIssuedKey":"2015","dateIssuedDisp":"2015-","publisher":"AME Publishing Company ; Pioneer Bioscience Publ.","publisherPlace":"Hong Kong ; Hong Kong"}],"note":["Gesehen am 10.11.25"],"recId":"635603896","language":["eng"],"id":{"issn":["2077-6624"],"eki":["635603896"],"zdb":["2573571-8"]}}],"recId":"1577797191"} | ||
| SRT | |a CHRISTOPOUMIGHTYOAKI0920 | ||